Anzeige
Mehr »
Donnerstag, 04.12.2025 - Börsentäglich über 12.000 News
Investitions-Update: Giant Mining Corp. setzt Segel für die Zukunft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P4TH | ISIN: SE0014401378 | Ticker-Symbol: 1AD1
Frankfurt
03.12.25 | 08:04
16,640 Euro
-1,30 % -0,220
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ADDLIFE AB Chart 1 Jahr
5-Tage-Chart
ADDLIFE AB 5-Tage-Chart
RealtimeGeldBriefZeit
16,35016,60003.12.
GlobeNewswire (Europe)
75 Leser
Artikel bewerten:
(0)

AddLife AB: AddLife acquires Pharmacold A/S

AddLife acquires Pharmacold A/S, a leading Danish specialist in refrigeration technology and service for the pharmaceutical and healthcare sectors. Pharmacold will become a subsidiary of Holm & Halby, a company within AddLife's business Area Labtech.

Pharmacold delivers advanced, customised solutions for temperature-controlled storage, including installation, service, and support of refrigeration and freezer systems, climate control systems, and mobile low-temperature units. The company brings extensive experience in managing critical and highly customised installations for the pharmaceutical and research sectors, where stable operation and documented quality are essential. Pharmacold, with a current revenue of EUR 3.4 million, operates primarily in Denmark.

The acquisition supports AddLife's strategic initiative to strengthen the service business and is aligned with previously communicated acquisition criteria.

"The acquisition of Pharmacold, together with Holm & Halby's Cold Storage division, enables us to offer a broader and more comprehensive product portfolio. Holm & Halby's extensive customer network and deep expertise in quality and regulatory matters also present significant opportunities for Pharmacold's future growth. We look forward to further developing our product and service offerings and strengthening our market position in Denmark," says Mattias Bengtsson, Vice President Biomedical and Research, AddLife.

"We are enthusiastic about the new opportunities and expertise that AddLife brings to Pharmacold. Becoming part of Holm & Halby and the AddLife family, with its strong market presence, opens exciting prospects for our company, our employees, suppliers, and customers," says Bjarne Nordbjerg, CEO and co-owner of Pharmacold. "I am excited to lead Pharmacold into this next chapter of our journey."

The acquisition was completed on December 1, 2025. The acquisition is expected to have a marginally positive effect on AddLife's earnings per share during the current financial year.

Stockholm, December 1, 2025
AddLife AB (publ)

For further information, please contact
Fredrik Dalborg, CEO, fredrik.dalborg@add.life, +46 70 516 09 01
Christina Rubenhag, CFO, christina.rubenhag@add.life, +46 70 546 72 22
www.add.life

About Holm & Halby:
Holm & Halby distributes and services laboratory equipment for research laboratories within the pharmaceutical industry, hospitals and higher education establishments for over 70 years. One of Holm & Halby's dedicated sales teams sells and services cooling and freezing cabinets to the pharmaceutical industry. Holm & Halby has built a robust service department with a dedicated team of technicians and consultants, who are certified to offer quality service and regulatory expertise.

About Pharmacold:
Pharmacold provides advanced, tailored systems for temperature-controlled storage, including the installation, servicing and support of cooling and freezing units, climate control systems and mobile low-temperature equipment. The company has extensive experience operating within GxP-regulated environments, where reliability, compliance and complete documentation are essential requirements.

About AddLife:
AddLife is an independent partner in the Life Science industry that offers high-quality products, services and advice to both the private and public sectors in Europe. AddLife has 2,300 employees in about 85 operating subsidiaries. The Group currently has net sales of more than SEK 10 billion. AddLife shares are listed on Nasdaq Stockholm.

The information in this press release was submitted for publication on December 1, 2025, at 14:00 (CET).

© 2025 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.